Search

Your search keyword '"Gimenez-Arnau, Ana"' showing total 393 results

Search Constraints

Start Over You searched for: Author "Gimenez-Arnau, Ana" Remove constraint Author: "Gimenez-Arnau, Ana"
393 results on '"Gimenez-Arnau, Ana"'

Search Results

3. Occupational Contact Urticaria Syndrome

6. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

9. Drug Photosensitivity

10. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials

13. Patients With Chronic Spontaneous Urticaria Who Have Wheals, Angioedema, or Both, Differ Demographically, Clinically, and in Response to Treatment—Results From CURE

14. Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study

15. Urticarial Vasculitis Differs From Chronic Spontaneous Urticaria in Time to Diagnosis, Clinical Presentation, and Need for Anti-Inflammatory Treatment: An International Prospective UCARE Study

16. The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria—CURE Results

17. Contact Dermatitis: Overcoming Challenges of Specific Patients, Deciphering the Results and Reaching a Correct Diagnosis

20. Biological drugs for the treatment of children with chronic spontaneous urticaria.

27. How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study

29. The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study

31. Safety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis (P8-6.015)

32. Enhancing Angioedema Patient Care: Unveiling Underutilization and Barriers in the Implementation of Patient-Reported Outcome Measurements

34. Efficacy of Remibrutinib in Patients With Chronic Spontaneous Urticaria With or Without Prior Exposure to Biologics in the Phase 3 REMIX-1 and REMIX-2 Studies

36. Time to Relapse During Treatment-Free Follow-Up Without Remibrutinib in Patients With Chronic Spontaneous Urticaria: Subgroup Analysis By Baseline Immunoglobulin-E Levels and Chronic Urticaria Index Status From a Phase 2b Extension Study

39. Essentials and Updated Concepts

41. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials

42. CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

43. CRUSE®-An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

44. 156. Safety of Remibrutinib across Immune-mediated Diseases Supports Development in Multiple Sclerosis

46. CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

47. Emerging Systemic Treatment Options in Atopic Dermatitis.

48. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials

49. Usage prevalence of angioedema patient–reported outcome measures: Results from the UCARE and ACARE PROMUSE study

Catalog

Books, media, physical & digital resources